| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| LEVI STRAUSS & CO | Director | Class A Common Stock | 172,701 | $4,023,933 | $23.30 | 04 Nov 2025 | Direct |
| LEVI STRAUSS & CO | Director | Class B Common Stock | 14,196 | $2,197,734 | $17.93 | 04 Nov 2025 | Direct |
| Revance Therapeutics, Inc. | Director | Common Stock | 0 | $0 | $3.65 | 06 Feb 2025 | Direct |
| Revance Therapeutics, Inc. | Director | Stock Option (Right to buy) | 23,458 | 01 May 2024 | Direct |